[Progress in hematopoietic stem cell transplantation for acute myeloid leukemia]

Area of Science:

• Hematology
• Oncology
• Stem Cell Transplantation

Background:

• Acute myeloid leukemia (AML) is a cancer of myeloid hematopoietic stem/progenitor cells.
• Despite new drug developments, hematopoietic stem cell transplantation (HSCT) remains a cornerstone therapy for AML.
• Relapsed and refractory AML pose significant treatment challenges.

Purpose of the Study:

• To review current advancements and future directions in HSCT for AML.
• To discuss the optimization of HSCT strategies for various AML patient groups.
• To highlight the integration of novel therapies with HSCT.

Main Methods:

• Review of recent literature on HSCT in AML.
• Analysis of updated indications, donor selection criteria, and conditioning regimens.
• Evaluation of new strategies for relapse prevention and treatment intensification.

Main Results:

• HSCT indications for AML are evolving, with refined donor selection and conditioning regimens.
• Novel strategies including targeted drugs and immunotherapy combined with HSCT show promise for relapsed/refractory AML.
• Transplantation technology optimization is crucial for elderly AML patients.

Conclusions:

• HSCT remains an irreplaceable treatment modality for acute myeloid leukemia.
• Integration of new drugs and immunotherapies with HSCT significantly improves prognosis.
• Personalized HSCT approaches are essential for optimizing outcomes in AML, especially in elderly patients.